Abstract | BACKGROUND: METHODS: A systematic search was performed in PubMed, Cochrane Library, EMBASE, Medline, Web of Science and Science Direct databases from January 2000 to October 2021 for controlled trials of BPH patients comparing oral desmopressin with control groups. The mean difference (MD) and odds ratio (OR) were meta-analyzed. RESULTS: Four articles with 500 patients were included. Significantly greater benefit was detected for the desmopressin group in the improvement of nocturia (P = .004), international prostate symptom score - storage (IPSS-S) (P = .03), and quality of life (QoL) (P = .04) scores. Patients treated with desmopressin were at higher risk than the control group for short-term adverse events (P < .001), including nausea (4.71%, P = .04), headache (20%, P < .00001), dizziness (5.88%, P = .02) and hyponatremia (4.71%, P = .04), but the long-term incidence might decrease. CONCLUSION:
|
Authors | Qihua Wang, Rami Alshayyah, Bo Yang |
Journal | Lower urinary tract symptoms
(Low Urin Tract Symptoms)
Vol. 14
Issue 3
Pg. 155-162
(May 2022)
ISSN: 1757-5672 [Electronic] Australia |
PMID | 35034423
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2022 John Wiley & Sons Australia, Ltd. |
Chemical References |
- Deamino Arginine Vasopressin
|
Topics |
- Deamino Arginine Vasopressin
(adverse effects)
- Dizziness
(complications)
- Headache
(complications)
- Humans
- Hyponatremia
(complications)
- Male
- Nausea
(complications)
- Nocturia
(drug therapy, etiology)
- Prostatic Hyperplasia
(complications, drug therapy)
- Quality of Life
- Treatment Outcome
|